The University of Western Australia Patent applications |
Patent application number | Title | Published |
20160045554 | METHOD FOR GENERATING MATURE BETA-LIKE CELLS - The present invention relates to methods for generating mature insulin-producing β-like cells comprising the steps: (a) isolating, purifying and/or enriching β-cell progenitor cells from a population of cells; (b) differentiation of the β-cell progenitor cells into immature insulin-producing β-like cells; and (c) maturation of the immature insulin-producing β-like cells into mature insulin-producing β-like cells, comprising exposing the immature insulin-producing β-like cells to calcitriol or an analogue thereof. More particularly, the present invention relates to methods for generating mature insulin-producing β-like cells for use in treating diabetes. | 02-18-2016 |
20150126581 | MicroRNAs and Uses Thereof - Provided herein are methods for inhibiting expression of DOHH in a cell, and for inhibiting hypusination of eIF5A in a cell, the methods comprising contacting a cell with a miRNA or a nucleic acid molecule encoding the miRNA, wherein the miRNA binds to the 3′UTR of the DOHH mRNA and wherein binding results in a reduction in DOHH expression. Also provided are methods for reducing cellular proliferation and for treating diseases associated with abnormal cellular proliferation. | 05-07-2015 |
20150057330 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 02-26-2015 |
20150017861 | COLLAGEN SCAFFOLD FOR CELL GROWTH AND A METHOD FOR PRODUCING SAME - A bioscaffold and method of manufacture is described. The bioscaffold has greater than 80% type I collagen fibers or bundles having a knitted structure providing tensile load strength. A method of manufacture incorporates the steps of: (a) isolating collagen fibers or bundles; (b) incubating the fibers or bundles in a mixture of NaOH, alcohol, acetone, HCl and ascorbic acide; and (c) mechanical manipulation of the fibers or bundles to produce knitted structure. | 01-15-2015 |
20140350067 | ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59. | 11-27-2014 |
20140316237 | METHOD FOR CHARACTERISING A MECHANICAL PROPERTY OF A MATERIAL - A method for characterising a mechanical property of a material. The method comprises the steps of providing the material having a deformable portion and providing a device having an optical element that is arranged to detect electromagnetic radiation. | 10-23-2014 |
20140249049 | USE OF CD5 ANTIGEN-LIKE AS A BIOMARKER FOR DIABETIC NEPHROPATHY - Biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV. | 09-04-2014 |
20140243516 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 08-28-2014 |
20140243515 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 08-28-2014 |
20140155587 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 06-05-2014 |
20140080898 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - Antisense molecules capable of binding to a selected target site in the dystrophin gene to induce exon skipping are described. | 03-20-2014 |
20140050670 | MULTIFUNCTIONAL NANOPARTICLES - The invention provides a nanoparticle for delivery of therapeutic agents, comprising a polymeric nanosphere and one or more detection agents, said detection agents for use in detecting the location of the nanoparticle. The invention further provides a transfection agent comprising an aforementioned nanoparticle. | 02-20-2014 |
20130331438 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 12-12-2013 |
20130323813 | PEPTIDES FOR THE SPECIFIC BINDING OF RNA TARGETS - A recombinant polypeptide is described including at least one PUF RNA-binding domain capable of specifically binding to a cytosine RNA base. The PUF RNA-binding domain of the polypeptide includes at least one RNA base-binding motif of the general formula X | 12-05-2013 |
20130289282 | THIN FILM TUBE REACTOR - A thin film tube reactor comprising a tube having a longitudinal axis, an inner cylindrical surface, a closed end and an open end, wherein the tube is rotatable about the longitudinal axis and wherein the angle of the longitudinal axis relative to the horizontal is variable between about 0 degrees and about 90 degrees. | 10-31-2013 |
20130253180 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - Antisense molecules capable of binding to a selected target site in the dystrophin gene to induce exon skipping are described. | 09-26-2013 |
20130253033 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 09-26-2013 |
20130217755 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 08-22-2013 |
20130177544 | BIOMARKERS ASSOCIATED WITH PRE-DIABETES, DIABETES AND DIABETES RELATED CONDITIONS - Biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV. | 07-11-2013 |
20130116310 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 05-09-2013 |
20120329871 | ANTIMICROBIAL COMPOUNDS - A compound for use as an antimicrobial having a formula (A). | 12-27-2012 |
20120270925 | ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59. | 10-25-2012 |
20120093877 | COLLAGEN SCAFFOLD FOR CELL GROWTH AND A METHOD FOR PRODUCING SAME - A bioscaffold and method of manufacture is described. The bioscaffold comprised greater than 80% type I collagen fibers or bundles having a knitted structure providing tensile load strength. The method of manufacture comprises the steps of: (a) isolating collagen fibers or bundles; (b) incubating said fibers or bundles in a mixture of NaOH, alcohol, acetone, HC; and ascorbic acid; and (c) mechanical manipulation of said fibers or bundles to produce a knitted structure. | 04-19-2012 |
20120041050 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 02-16-2012 |
20120029060 | Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 02-02-2012 |
20120029059 | Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 02-02-2012 |
20120029058 | Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 02-02-2012 |
20120029057 | Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 02-02-2012 |
20120022145 | Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 01-26-2012 |
20120022144 | Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 01-26-2012 |
20110263686 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 10-27-2011 |
20110046203 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 02-24-2011 |
20110044770 | MESH SYSTEM - There is provided a mesh system ( | 02-24-2011 |
20110015258 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 01-20-2011 |
20110015253 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF - An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202. | 01-20-2011 |
20100166870 | Method for Coating Nanoparticles - A method of coating nanoparticles comprising subjecting nanoparticles, a coating precursor and one or more reagents to shear, wherein the coating precursor and the one or more reagents react to provide a coating on the nanoparticles. | 07-01-2010 |
20100166624 | METHODS FOR SELECTIVELY SEPARATING CARBON NANOTUBES - A method of separating at least one carbon nanotube having a desired diameter and/or chirality from a mixture of carbon nanotubes having different diameters and/or chiralities is provided. A calixarene of formula (I): | 07-01-2010 |
20090312245 | SRA binding protein - An isolated polypeptide comprising: (i) SEQ ID No: 2; (ii) amino acids 27 to 109 of SEQ ID No: 2 (iii) amino acids 22 to 109 of SEQ ID No: 2 (iv) amino acids 21-91 of SEQ ID No: 2 (v) amino acids 21-26 and/or 60-67 of SEQ ID No: 2 or (vi) a functional variant of any one of (i) to (v). | 12-17-2009 |
20090191161 | TENOCYTE CELL CULTURING METHOD - The present invention relates to a method for culturing tenocytes. In particular the present invention relates to a method for culturing tenocytes comprising the step of incubating tenocytes in a culture medium comprising insulin or functional derivative. | 07-30-2009 |
20090185746 | IMAGE RECOGNITION - An image recognition method and system ( | 07-23-2009 |
20090170771 | Anti-angiogenic agents and methods of their use - The present invention relates to the use of sFRP-4 and functional variants thereof as anti-angiogenic agents. It relates to methods of treatment and screening methods using sFRP-4 and functional variants thereof. Further, it relates to compositions, and in particular pharmaceutical composition, including sFRP-4 and functional variants thereof which may be used in the various methods provided herein. | 07-02-2009 |